Navigation Links
StockCall Scrutinizes Pfizer, Merck & Co., Johnson & Johnson, and AbbVie

LONDON, April 10, 2013 /PRNewswire/ --

The Dow Jones Index closed at an all time high at 14,673.46, up 0.41 percent while NASDAQ was up 0.48 percent to end yesterday's session at 3,237.86. Similarly, S&P also finished Tuesday's trading session on a positive note at 1,568.61, up 0.35 percent. The markets showed across the board improvement and a bullish trend. Our research team took a look at the Healthcare sector, focusing on the major drug makers industry which include including companies like Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ) and AbbVie Inc. (NYSE: ABBV). StockCall reviewed the Drug Manufacturers - Major industry and chose PFE, MRK, JNJ, and ABBV for its technical coverage. These free reports can be seen for free at

Pfizer Inc. is trading below its long-term moving average price, indicating a neutral trend. It also closed its latest trading session at $29.11, down 0.17 percent. The stock made its downward movement with below average volume of 27.53 million shares. Pfizer Inc. trades at Price/Earnings ratio of 23.10, in-line with industry average, making the stock a fairly priced proposition. However, the stock provided good return to its holders as it appreciated 16.95 percent this year. Pfizer's stock also gained 30.3 percent in the past 52 weeks, and it oscillated between $21.40 and $29.44 during this time period. Download the free research on PFE by signing up now at

Merck & Co. Inc. is currently trading in overbought territory with its Relative Strength Index at 70.18. Consequently, the stock may see some pullback in the coming sessions. It closed its Tuesday's session at $45.51, up 0.07 percent. The stock is currently in a bullish mode and may touch $45.67 level in the coming days. Upon breaching this level, the stock's next resistance price is at $47.96. the drug maker's stock has low volatility with its beta at 0.58. So far in 2013, the stock appreciated 11.98 percent. Its 52 weeks gain stands at 17.05 percent. The stock has traded in the range of $37.02 and $48 during the said time period. Register for today's free analysis on MRK at

Johnson & Johnson extended its 52 weeks gain by closing 0.51 percent higher. The stock ended Tuesday's session at $81.52, while its highest price point for the session stood at $81.75. It traded 9.08 million shares, down from its average daily volume of 9.98 million. Johnson & Johnson traded in the range of $61.71 and $82.95 in the past 52 weeks, and currently it is trading near its high price point. The company commands market capitalization of $228.01 billion and it reported its latest EPS at $3.86. Johnson & Johnson's stock gained more than 24 percent in the past 52 weeks. Free report on JNJ can be accessed by registering at

AbbVie Inc. traded up with above average volume to end its latest session at $42.55. The stock ended 1.87 percent higher than its previous close. Its volume for the day stood at 8.67 million shares. The stock is currently trading marginally lower than its 20-day SMA of $42.58 and its 50-day SMA of $42.77. Its first resistance level is at $42.87 while it may tumble down to $42.33 before receiving any support. AbbVie's stock is up 23.26 percent on a YTD basis, while offering 3.76 percent dividend yield. Register with StockCall and download the research on ABBV for free at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at  

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Leaders from Pfizer, Novartis and J&J Challenge Industry to Disrupt R&D
2. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
3. Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates
4. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
5. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
6. Merck Serono et lInstitut Feinstein vont sassocier pour développer un programme pré-clinique portant sur les maladies inflammatoires
7. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
11. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
Breaking Biology Technology:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
Breaking Biology News(10 mins):